These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1633300)

  • 1. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
    Shapiro ME; Kirkman RL; Kelley VR; Bacha P; Nichols JC; Strom TB
    Targeted Diagn Ther; 1992; 7():383-93. PubMed ID: 1633300
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant toxins.
    Kreitman RJ; Pastan I
    Adv Pharmacol; 1994; 28():193-219. PubMed ID: 8080817
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of cytotoxin interleukin-2-pseudomonas exotoxin 66 on corneal allograft rejection in mice].
    Wu J; Yu J
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2152-5. PubMed ID: 19923053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
    Meneghetti CM; LeMaistre CF
    Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment with a diphtheria toxin-related interleukin 2 fusion protein prolongs cardiac allograft survival in mice.
    Barrett LV; Murphy JR; Strom TB; Kirkman RL
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1130-1. PubMed ID: 2650076
    [No Abstract]   [Full Text] [Related]  

  • 6. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
    [No Abstract]   [Full Text] [Related]  

  • 7. [An experimental study of corneal allograft rejection with cytotoxin IL-2-PE40].
    Wu J; Zhou G
    Zhonghua Yan Ke Za Zhi; 1995 Sep; 31(5):370-3. PubMed ID: 8706588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease.
    Murphy JR; Lakkis FG; vanderSpek JC; Anderson P; Strom TB
    Targeted Diagn Ther; 1992; 7():365-82. PubMed ID: 1633299
    [No Abstract]   [Full Text] [Related]  

  • 9. Recombinant fusion toxins--a new class of targeted biologic therapeutics.
    Woodworth TG; Nichols JC
    Cancer Treat Res; 1993; 68():145-60. PubMed ID: 8105849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
    Chiron MF
    Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
    Bunn PA
    Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
    [No Abstract]   [Full Text] [Related]  

  • 12. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy.
    Ramadan MA; Gabr NS; Bacha P; Günzler V; Phillips SM
    Cell Immunol; 1995 Dec; 166(2):217-26. PubMed ID: 7497523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant toxins as novel therapeutic agents.
    Pastan I; Chaudhary V; FitzGerald DJ
    Annu Rev Biochem; 1992; 61():331-54. PubMed ID: 1497314
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversal of acute allograft rejection using immunotoxin.
    Knechtle SJ; Fechner JH; Stavrou S; Neville DM; Dong Y; Hong X; Tsuchida M; Hamawy MM
    Transplant Proc; 1998 Aug; 30(5):2150-1. PubMed ID: 9723422
    [No Abstract]   [Full Text] [Related]  

  • 16. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
    Kuzel TM
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant toxins for the treatment of cancer.
    Kreitman RJ
    Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
    Kreitman RJ
    BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.
    Potala S; Sahoo SK; Verma RS
    Drug Discov Today; 2008 Sep; 13(17-18):807-15. PubMed ID: 18678276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxins and cytokine toxin fusion proteins.
    Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
    Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.